Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1174-1179

  Lillibridge, James A ^a   Kalhorn, Thomas F ^a   Slattery, John T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLYCOL; LISOFYLLINE; LYSOPHOSPHATIDIC ACID; PENTOXIFYLLINE; PHOSPHATIDIC ACID; PRODRUG;

ADULT; ARTICLE; BLOOD RHEOLOGY; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; ENTERIC COATED TABLET; FEMALE; HUMAN; HUMAN TISSUE; INTERMITTENT CLAUDICATION; LIVER CYTOSOL; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOISOMERISM;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; PENTOXIFYLLINE;

EID: 0030476589     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. E. Ernst: Pentoxifylline for intermittent claudication: a critical review. Angiology 45, 339-345 (1994).
2. J. A. Bianco, F. R. Appelbaum, J. Nemunaitis, J. Almgren, F. Andrews, P. Kettner, A. Shields, and J. W. Singer: Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78, 1205-1211 (1991).
3. J. A. Thompson, J. A. Bianco, M. C. Benyunes, M. A. Neubauer, J. T. Slattery, and A. Fefer: Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res. 54, 3436-3441 (1994).
4. J. Tesarik and C. Mendoza: Sperm treatment with pentoxifylline improves the fertilizing ability in patients with acrosome reaction insufficiency. Fertil. Steril. 60, 141-148 (1993).
5. H. Tournaye, A. C. Van Steirteghem, and P. Devroey: Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum. Reprod. 9, 996-1000 (1994).
6. B. J. Dezube: Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 18, 285-287 (1994).
7. R. K. Campbell: Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease. Ann. Pharmacother. 27, 1099-1105 (1993).
8. D. Landman, A. Sarai, and S. S. Sathe: Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin. Infect. Dis. 18, 97-99 (1994).
9. M. Attal, F. Huguet, H. Rubie, J. P. Charlet, D. Schlaifer, A. Huynh, G. Laurent, and J. Pris: Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82, 732-736 (1993).
10. R. H. C. van der Jagt, G. Pari, S. A. McDiarmid, D. M. Boisvert, and L. B. Huebsch: Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 13, 203-207 (1994).
11. R. A. Clift, J. A. Bianco, F. R. Appelbaum, C. D. Buckner, J. W. Singer, L. Bakke, W. I. Bensinger, R. A. Bowden, G. B. McDonald, M. Schubert, A. F. Shields, J. T. Slattery, R. Storb, L. D. Fisher, M. Mori, E. D. Thomas, and J. A. Hansen: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 82, 2025-2030 (1993).
12. G. C. Rice, P. A. Brown, R. J. Nelson, J. A. Bianco, J. W. Singer, and S. Bursten: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Natl Acad. Sci. U.S.A. 91, 3857-3861 (1994).
13. H. J. Von Hinze, G. Bedebem, and A. Söder: Struktur der ausscheidungsprodukte des 3,7-dimethyl-1-(5-oxo-hexyl)-xanthins (BL 191) beim menschen. Arzneimittelforschung 22, 1144-1151 (1972).
14. 14C-pentoxifylline in healthy volunteers. Arzneimittelforschung 39, 512-517 (1989).
15. A. Mancinelli, S. Pace, A. Marzo, and E. Arrigoni Martelli: Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. J. Chromatogr. 575, 101-107 (1992).
16. J. D. Cleary: Ciprofloxacin (Cipro) and pentoxifylline (PTF): a clinically significant drug interaction. Pharmacotherapy 12, 259 (1992).
17. J. W. Singer, A. List, D. Federighi, T. Michnick, and S. Bursten: Serum hydroperoxy and hydroxyoctadecadienoic acids (HPODE and HODE) increase in response to total body irradiation and are suppressed by lisofylline in allogeneic BMT patients. Blood, in press.
18. K. Waxman, K. Daughters, and S. Aswani: Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit. Care Med. in press.
19. E. Abraham, S. Bursten, R. Shenkar, J. Allbee, R. Tuder, P. Woodson, D. M. Guidot, G. Rice, J. W. Singer, and J. E. Repine: Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J. Exp. Med. 181, 569-575 (1995).
20. K. E. Thummel, C. A. Lee, K. L. Kunze, S. D. Nelson, and J. T. Slattery: Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharamcol. 45, 1563-1569 (1993).
21. K. E. Thummel, E. D. Kharasch, T. Podoll, and K. Kunze: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21, 350-357 (1993).
22. R. L. Felsted and N. R. Bachur: Mammalian carbonyl reductases. Drug Metab. Rev. 11, 1-60 (1980).
23. G. Leimenstoll, P. Zabel, P. Schroeder, M. Schlaak, and W. Niedermayer: Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplant. Proc. 25, 561-563 (1993).
24. F. G. Vincenti, M. Vasconcelos, J. L. Birnbaum, S. J. Tomlanovich, W. J. C. Amend, Jr., J. S. Melzer, and J. P. Snyder: Pentoxifylline reduces the first-dose reactions following OKT3. Transplant. Proc. 25, 57-59 (1993).
25. L. Schandené, C. Gérard, A. Crusiaux, D. Abramowiczk T. Velu, and M. Goldman: Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant. Proc. 25, 55-56 (1993).
26. O. Pradier, D. Abramowicz, P. Capel, and M. Goldman: Procoagulant properties of OKT3 at the monocyte level: inhibition by pentoxifylline. Transplant. Proc. 25, 39-40 (1993).
27. P. Zabel, U. Greinert, P. Entzian, and M. Schlaak: Effects of pentoxifylline on circulating cytokines (TNF and IL-6) in severe pulmonary tuberculosis. In "Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance" (W. Fiers and W. A. Buurman, eds.), pp. 178-181. Basel, Karger, 1993.
28. D. Weill, H. Setiadi, M. P. Wautier, P. J. Guillausseau, F. Lioté, and J. L. Wautier: Pharmacological modulation of monocyte adhesion to endothelial cells. Clin. Hemorheol. 12, 713-724 (1992).
29. C. Fossat, D. Sainty, A. M. Stoppa, D. Maraninchi, and I. Juhan-Vague: Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. Nouv. Rev. Fr. Hematol. 34, S61-S64 (1992).